19 results on atopic dermatitis
Primary Objective: To investigate longitudinal variation of blood-based biomarkers, their integration with disease severity, comorbidities, their association with standard care and characterization of adequate and inadequate responders to standard…
PrimaryThe primary objective of this study is to assess the safety and tolerability of BEN2293, administered as multiple topical doses to increasing body surface area (BSA), in patients with mild to moderate AD.SecondaryPharmacokinetics· To…
Primary objective: To establish the PK profile after multiple SC administrations of tralokinumab in children with moderate-to-severe AD.Secondairy objectives: - To assess the safety and tolerability of multiple SC administrations of tralokinumab in…
Primary Objective Primary objective is to assess the efficacy of OM-85 versus matched placebo in children with moderate AD in reducing disease severity over the first 16 weeks and the first 24 weeks of the treatment period.Secondary Objectives…
The main aim of this project is to obtain a better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies.
1. Sub-Study 1 (SS1): The primary study objective for SS1 is to evaluate the efficacy and safety of dose escalation to upadacitinib 30 mg QD insubjects who do not achieve Eczema Area and Severity Index (EASI) 90 on upadacitinib 15 mg QD after 12…
Our primary objectives are to analyse the gene expression profile of non-lesional and lesional skin of patients with NS (ichthyosis linearis circumflexa (ILC) phenotype and scaly erythroderma (SE) phenotype) using single cell RNA sequencing and…
This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed.
As part of your treatment, you will receive DUPIXENT. We would like to learn what the experiences of patients are with this medical product and if you notice any changes. The aim of the study is to better understand the characteristics of patients…
The objective of this phase III study is to evaluate the efficacy and safety of Tozorakimab according to 300 mg every 8 weeks (Q8W) and 300 mg every 4 weeks (Q4W) dosing regimens administered in adult participants with symptomatic COPD and a history…
Comparing the effectiveness and cost-effectiveness of narrowband ultraviolet B with optimal topical therapy (NB-UVB+OTT) versus OTT at 3 months in adult patients with atopic eczema (AE).
Therefore, the purpose of our study is to study, in peanut and nut allergic children:1. the relationship between gut permeability and threshold levels to peanut or nuts;2. the effect of an immune-supportive diet on gut permeability, coexisting…
Primary• To evaluate the effect of EDP1815 (same dose using EC1 and EC2 capsules) and EDP2939 (two dose levels using EC2 capsules) on the immune system.Secondary• To evaluate the effect of EDP1815 (same dose using EC1 and EC2 capsules) and EDP2939 (…
• To evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers• To evaluate the effect of POLB 001 on inflammatory responses following an intravenous LPS challenge in healthy volunteers
Given the worldwide-observed rapid increase in the prevalence of allergic diseases, it is likely that environmental risk factors, including geographic area and lifestyle factors play a substantial role in the development of allergies and other…
• To investigate the microbiome composition of the nares, non-lesional skin and patches, plaques and tumours in lesional skin of CTCL patients, including all stages of the disease• Correlate microbiome (including S. aureus presence) and disease…
Sub-study APhase 1b:To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to determine the RP2D for the combination. Phase 2:To assess the durable ORR of sasanlimab in combination with encorafenib…
The purpose of the study is to evaluate how effective rilzabrutinib is and how safe it is, in reducing the signs and symptoms in patients with chronic spontaneous urticaria (CSU), who continue to have symptoms despite the use of H1-antihistamines (…
Primary Objective:1. To evaluate the efficacy of sonelokimab at 2 different dose levels (120 mg, 240 mg) compared with placebo in the treatment of participants withactive moderate to severe hidradenitis suppurativa.Secondary Objectives:1. To…